Essential Premium

Biopharma Funds Surge on Deals and Drug Breakthroughs

Goldman Sachs anticipates a continuation of the boom in mergers and acquisitions as cash-rich pharmaceutical giants look to replenish their shrinking drug pipelines.

The Pension Fixer Who Finally Got to Build His Own Portfolio

“When you get an opportunity to start a brand-new fund that was going to be over $10 billion from scratch, you take a second look,” says Illinois Police’s Kent Custer.

Sponsored

Capital Markets, Reframed: A Corporate Defined Benefit Perspective

Flight Deck Capital Soars 119 Percent Through June on Strength in AI Enablers

Onetime II Hedge Fund Rising Star Jay Kahn believes many AI-related stocks still have a long way to go.

Related Content

The Rich List: Institutional Investor’s 25th Annual Ranking of the Highest-Earning Hedge Fund Managers

Stephen Taub

Graham Capital’s Ken Tropin Named 2026 Hedge Fund Lifetime Achievement Award Winner

Michelle Celarier

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram